STRATA Skin Sciences

STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. It engages in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through the following segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STRATA Skin Sciences pursues growth through international expansion and profitability

STRATA Skin Sciences is strategically focusing on increasing revenue per device and expanding internationally to drive growth.
While facing challenges in domestic billings and lower revenue, the company's cost-cutting measures are enhancing profitability.
The company's efforts to optimize operations and drive revenue growth position it well for future success.

STRATA Skin Sciences reports revenue growth and operational improvements in Q2 2024

STRATA Skin Sciences (SSKN) delivered a mixed performance in Q2 2024 with revenue growth, improved operational efficiency, and strategic financing.
The company showcased strengths in equipment revenue growth, expanding customer base, and effective cost management strategies.
Challenges remain in achieving profitability, sustaining growth momentum, and managing operational costs effectively.
Opportunities lie in leveraging marketing efforts, expanding product offerings, exploring new markets, and optimizing operational efficiency for future growth.

STRATA Skin Sciences reports solid Q3 performance with growth opportunities

STRATA Skin Sciences demonstrated solid financial performance in Q3 2024, leveraging improved revenue per XTRAC and cost management.
While facing challenges in device adoption and operating expenses, the company's DTC initiatives and cash position present growth opportunities.
By focusing on enhancing device utilization and investing in innovation, STRATA Skin Sciences can drive future revenue growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HORSHAM, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Mr. Christopher Lesovitz, STRATA's current Controller, has been named Chief Financial officer. He succeeds Matthew Hill, who has decided to leave effective October 15, 2021 to pursue a new opportunity. Mr. Lesovitz will assume the role of Chief Financial Officer effective October 16.

STRATA Skin Sciences Announces CFO Transition

HORSHAM, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the Company will participate in two upcoming investor conferences.

STRATA Skin Sciences to Participate in Upcoming Investor Conferences

STRATA Skin Sciences, Inc. (SSKN) CEO Robert Moccia on Q2 2021 Results - Earnings Call Transcript

HORSHAM, Pa., Aug. 16, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the quarter ended June 30, 2021.

STRATA Skin Sciences Reports Second Quarter 2021 Financial Results

Ra Medical Systems Inc

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing its excimer laser system to treat vascular disease, announces the sale of its Pharos dermatology business to STRATA Skin Sciences (Nasdaq: SSKN) for $3.7 million in cash. The Pharos excimer laser is FDA-cleared for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. “We believe this transaction is in the best interest of Ra Medical and our sh

Ra Medical Systems Announces Sale of Pharos Dermatology Business

HORSHAM, Pa., Aug. 16, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the acquisition of the U.S. dermatology business of Ra Medical.

STRATA Skin Sciences Announces Acquisition of the U.S. Dermatology Business of Ra Medical Systems

Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Strata Skin Sciences, Inc. (SSKN) to Report a Decline in Earnings: What to Look Out for

HORSHAM, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its second quarter 2021 financial results after the market closes on Monday, August 16, 2021. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

STRATA Skin Sciences to Report Second Quarter 2021 Financial Results on August 16, 2021

HORSHAM, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the Company will participate in the upcoming Oppenheimer MedTech, Tools & Diagnostics Summit.

STRATA Skin Sciences to Participate in the Oppenheimer MedTech, Tools & Diagnostics Summit

STRATA Skin Sciences, Inc. (SSKN) CEO Robert Moccia on Q1 2021 Results - Earnings Call Transcript

HORSHAM, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the quarter ended March 31, 2021.

STRATA Skin Sciences Reports First Quarter 2021 Financial Results

Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

HORSHAM, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its first quarter 2021 financial results after the market closes on Wednesday, May 12, 2021. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

STRATA Skin Sciences to Report First Quarter 2021 Financial Results on May 12, 2021

HORSHAM, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of William D. Humphries to its Board of Directors.

STRATA Skin Sciences Appoints William D. Humphries to Its Board of Directors

STRATA Skin Sciences, Inc. (SSKN) CEO Robert Moccia on Q4 2020 Results - Earnings Call Transcript

Shares of Strata Skin Sciences (NASDAQ:SSKN) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 0.00% year over year to ($0.01), which beat the estimate of ($0.03).

Recap: Strata Skin Sciences Q4 Earnings

HORSHAM, Pa., March 24, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the quarter and full year ended December 31, 2020.

STRATA Skin Sciences Reports Fourth Quarter and Full Year 2020 Financial Results

The stock price of STRATA Skin Sciences Inc (NASDAQ: SSKN) has increased by over 15% pre-market. This is why it happened.

SSKN Stock Price Increases Over 15% Pre-Market: Why It Happened

AVENTURA, Fla.--(BUSINESS WIRE)--Accelmed fund II

Accelmed Partners Raises $400 Million to Invest in Commercial Stage HealthTech

Vitiligo Repigmentation Achieved in Five Treatments with XTRAC® Excimer Laser

STRATA Skin Sciences Announces Independent Study Published in the Journal of The European Academy of Dermatology and Venereology

HORSHAM, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its fourth quarter and full year financial results after the market closes on Wednesday, March 24, 2021. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

STRATA Skin Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 24, 2021

Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

New Agreement Expands STRATA's Global Reach and Brings Successful Recurring Revenue Model to the Chinese Dermatology Market New Agreement Expands STRATA's Global Reach and Brings Successful Recurring Revenue Model to the Chinese Dermatology Market

STRATA Skin Sciences Announces Expanded Distribution Agreement in China with Wuhan Miracle Laser Systems, Inc.

The stock price of STRATA Skin Sciences Inc (NASDAQ: SSKN) is trading at over 10% pre-market. This is why it happened.

SSKN Stock Price Increases Over 10% Pre-Market: Why It Happened

Preliminary, unaudited fourth quarter revenues in the range of $6.6 million to $6.8 million  Preliminary, unaudited fourth quarter recurring revenues in the range of $5.0 million to $5.2 million Worldwide installed base increased by 23 placements in the fourth quarter

News for STRATA Skin Sciences Stock (SSKN)